<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H6488213344DE434EA98BA1B223414F67" key="H" public-private="public"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>115 HR 1223 IH: Orphan Products Extension Now Accelerating Cures and Treatments Act of 2017</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2017-02-27</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">115th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 1223</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20170227">February 27, 2017</action-date><action-desc><sponsor name-id="B001257">Mr. Bilirakis</sponsor> (for himself, <cosponsor name-id="B001251">Mr. Butterfield</cosponsor>, and <cosponsor name-id="M001157">Mr. McCaul</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend the Federal Food, Drug, and Cosmetic Act to authorize an extension of exclusivity periods
			 for certain drugs that are approved for a new indication for a rare
			 disease or condition, and for other purposes.</official-title></form>
	<legis-body id="H475FE2A5E5E84420BBEE0BAEB694A0DF" style="OLC">
 <section id="H3D1940164A214C77A9AFCDC5EA7487A5" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Orphan Products Extension Now Accelerating Cures and Treatments Act of 2017</short-title></quote> or the <quote><short-title>OPEN Act</short-title></quote>.</text> </section><section id="H48A742D5280C4D1F89015520E321FB41"><enum>2.</enum><header>Extension of exclusivity periods for a drug approved for a new indication for a rare disease or condition</header> <subsection id="H6246B97154B34867B9B2C23DD3CE0E89"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">The Federal Food, Drug, and Cosmetic Act is amended by inserting after section 505F of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355g">21 U.S.C. 355g</external-xref>) the following:</text>
				<quoted-block display-inline="no-display-inline" id="HA6379FB109644D379E20F571B11EAB62" style="OLC">
					<section id="HE034EB6439B547CCA65F7FC5EC83A0A3"><enum>505G.</enum><header>Extension of exclusivity periods for a drug approved for a new indication for a rare disease or
			 condition</header>
						<subsection id="HD397E8ED926343F199F8C65787E74D7F"><enum>(a)</enum><header>Designation</header>
 <paragraph id="H4EB74C7BDB6E4FCEB1C730DC370606BE"><enum>(1)</enum><header>In general</header><text>The Secretary shall designate a drug as a drug approved for a new indication to prevent, diagnose, or treat a rare disease or condition for purposes of granting the extensions under subsection (b) if—</text>
 <subparagraph commented="no" id="H1EC78B33FBCC41498C29409974857249"><enum>(A)</enum><text display-inline="yes-display-inline">prior to approval of an application or supplemental application for the new indication, the drug was approved or licensed under section 505(c) of this Act or section 351(a) of the Public Health Service Act but was not so approved or licensed for the new indication;</text>
								</subparagraph><subparagraph id="H1DE9B6BD2B894307AA58739A33FD9DAD"><enum>(B)</enum>
 <clause commented="no" display-inline="yes-display-inline" id="H255B2D6D31624AF9A82AA91E0B1A7A44"><enum>(i)</enum><text>the sponsor of the approved or licensed drug files an application or a supplemental application for approval of the new indication for use of the drug to prevent, diagnose, or treat the rare disease or condition; and</text>
 </clause><clause commented="no" id="H357BD584F51F4EF6B62D8A91930038C5" indent="up1"><enum>(ii)</enum><text>the Secretary approves the application or supplemental application; and</text> </clause></subparagraph><subparagraph id="HD6E03931E8814CD6A984F6FDC2CE5ADA"><enum>(C)</enum><text display-inline="yes-display-inline">the application or supplemental application for the new indication contains the consent of the applicant to public notice under paragraph (4) with respect to the designation of the drug.</text>
								</subparagraph></paragraph><paragraph id="H064DA361CB2F4E00BBE54C27A28361E7"><enum>(2)</enum><header>Revocation of designation</header>
 <subparagraph id="H5A21B83009E146FC8109EF8EC46DA8E6"><enum>(A)</enum><header>In general</header><text>Except as provided in subparagraph (B), a designation under paragraph (1) shall not be revoked for any reason.</text>
 </subparagraph><subparagraph id="HFD5E3222743940058FBF96DADDDD85CF"><enum>(B)</enum><header>Exception</header><text>The Secretary may revoke a designation of a drug under paragraph (1) if the Secretary finds that the application or supplemental application resulting in such designation contained an untrue statement of material fact.</text>
 </subparagraph></paragraph><paragraph id="H3367AA39D6BA443189EDC49F65460980"><enum>(3)</enum><header>Notice to public</header><text>The Secretary shall provide public notice of the designation of a drug under paragraph (1).</text> </paragraph></subsection><subsection id="H62A10FFCEBC44B31BAAF58CD3CA6F9E1"><enum>(b)</enum><header>Extension</header> <paragraph id="HE345C2A8A1F147DD835D33B67C662662"><enum>(1)</enum><header>In general</header><text>If the Secretary designates a drug as a drug approved for a new indication for a rare disease or condition, as described in subsection (a)(1)—</text>
								<subparagraph id="H3C79039110F54291BFD5C6B4BE1C7DC3"><enum>(A)</enum>
 <clause commented="no" display-inline="yes-display-inline" id="H75342D4C29144ED2B9A8C2FE39968026"><enum>(i)</enum><text>the 4-, 5-, and 7<fraction>½</fraction>-year periods described in subsections (c)(3)(E)(ii) and (j)(5)(F)(ii) of section 505, the 3-year periods described in clauses (iii) and (iv) of subsection (c)(3)(E) and clauses (iii) and (iv) of subsection (j)(5)(F) of section 505, and the 7-year period described in section 527, as applicable, shall be extended by 6 months; or</text>
 </clause><clause id="H97C1806BA1DB47BCA17265B9BC10D5F6" indent="up1"><enum>(ii)</enum><text display-inline="yes-display-inline">the 4- and 12-year periods described in subparagraphs (A) and (B) of section 351(k)(7) of the Public Health Service Act and the 7-year period described in section 527, as applicable, shall be extended by 6 months; and</text>
									</clause></subparagraph><subparagraph id="H2E4D80DE5E624813BEC25C76DE72C338"><enum>(B)</enum>
 <clause commented="no" display-inline="yes-display-inline" id="H417CCB94A9F5462AAADBB588586EF281"><enum>(i)</enum><text>if the drug is the subject of a listed patent for which a certification has been submitted under subsection (b)(2)(A)(ii) or (j)(2)(A)(vii)(II) of section 505 or a listed patent for which a certification has been submitted under subsection (b)(2)(A)(iii) or (j)(2)(A)(vii)(III) of section 505, the period during which an application may not be approved under section 505(c)(3) or section 505(j)(5)(B) shall be extended by a period of 6 months after the date the patent expires (including any patent extensions); or</text>
 </clause><clause id="H5C9D72CFB6FB47FA969F60178ED33363" indent="up1"><enum>(ii)</enum><text>if the drug is the subject of a listed patent for which a certification has been submitted under subsection (b)(2)(A)(iv) or (j)(2)(A)(vii)(IV) of section 505, and in the patent infringement litigation resulting from the certification the court determines that the patent is valid and would be infringed, the period during which an application may not be approved under section 505(c)(3) or section 505(j)(5)(B) shall be extended by a period of 6 months after the date the patent expires (including any patent extensions).</text>
 </clause></subparagraph></paragraph><paragraph id="H1F8DAF46EEF54AF4B8712D31B8297AEB"><enum>(2)</enum><header>Relation to pediatric and qualified infectious disease product exclusivity</header><text>Any extension under paragraph (1) of a period shall be in addition to any extension of the periods under sections 505A and 505E of this Act and section 351(m) of the Public Health Service Act, as applicable, with respect to the drug.</text>
 </paragraph></subsection><subsection id="H53D19E2E6A8C460A81FF08FA77F23DAF"><enum>(c)</enum><header>Limitations</header><text>Any extension described in subsection (b)(1) shall not apply if the drug designated under subsection (a)(1) has previously received an extension by operation of subsection (b)(1).</text>
 </subsection><subsection id="HA34C6B55B73E4E39B35D6E460C6C53A8"><enum>(d)</enum><header>Definition</header><text>In this section, the term <term>rare disease or condition</term> has the meaning given to such term in section 526(a)(2).</text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block> </subsection><subsection id="H6AA366D4920344F7BCECF5E25D5DC994"><enum>(b)</enum><header>Application</header><text display-inline="yes-display-inline">Section 505G of the Federal Food, Drug, and Cosmetic Act, as added by subsection (a), applies only with respect to a drug for which an application or supplemental application described in subsection (a)(1)(B)(i) of such section 505G is first approved under section 505(c) of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355(c)</external-xref>) or section 351(a) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(a)</external-xref>) on or after the date of the enactment of this Act.</text>
			</subsection><subsection id="HCB8354E065774DE793B50A99F0F0DD0D"><enum>(c)</enum><header>Conforming amendments</header>
 <paragraph id="HEE0BBD95F77C42388EFF187D72E29A19"><enum>(1)</enum><header>Relation to pediatric exclusivity for drugs</header><text display-inline="yes-display-inline">Section 505A of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355a">21 U.S.C. 355a</external-xref>) is amended—</text> <subparagraph id="H763770D775814D3584AEA26AB1803050"><enum>(A)</enum><text>in subsection (b), by adding at the end the following:</text>
						<quoted-block display-inline="no-display-inline" id="HD2ABABE2FE0E40F1B1E4AE1AB51E465B" style="OLC">
 <paragraph id="HF0E4A502A60D4AE787917C594467F15A"><enum>(3)</enum><header>Relation to exclusivity for a drug approved for a new indication for a rare disease or condition</header><text display-inline="yes-display-inline">Notwithstanding the references in paragraph (1) to the lengths of the exclusivity periods after application of pediatric exclusivity, the 6-month extensions described in paragraph (1) shall be in addition to any extensions under section 505G.</text></paragraph><after-quoted-block>; and</after-quoted-block></quoted-block>
 </subparagraph><subparagraph id="H09042523038540A6B4E55207FD970829"><enum>(B)</enum><text>in subsection (c), by adding at the end the following:</text> <quoted-block display-inline="no-display-inline" id="H9A753DB1FEFA4C3285E04BC84F765519" style="OLC"> <paragraph id="H5160026492CE453FBF9619013595771D"><enum>(3)</enum><header>Relation to exclusivity for a drug approved for a new indication for a rare disease or condition</header><text display-inline="yes-display-inline">Notwithstanding the references in paragraph (1) to the lengths of the exclusivity periods after application of pediatric exclusivity, the 6-month extensions described in paragraph (1) shall be in addition to any extensions under section 505G.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
 </subparagraph></paragraph><paragraph id="HA2DA491460D44616A87DB9E02FA48FDD"><enum>(2)</enum><header>Relation to exclusivity for new qualified infectious disease products that are drugs</header><text>Subsection (b) of section 505E of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355f">21 U.S.C. 355f</external-xref>) is amended—</text>
 <subparagraph id="HAC317FC450554F28924CD37D2BCCEFE8"><enum>(A)</enum><text>by amending the subsection heading to read as follows: <quote><header-in-text level="subsection" style="OLC">Relation to pediatric exclusivity and exclusivity for a drug approved for a new indication for a rare disease or condition.—</header-in-text></quote>; and</text>
 </subparagraph><subparagraph id="H1690FBDFC30D438CAB350A70866AC5B7"><enum>(B)</enum><text>by striking <quote>any extension of the period under section 505A</quote> and inserting <quote>any extension of the periods under sections 505A and 505G, as applicable,</quote>.</text> </subparagraph></paragraph><paragraph id="H2E5788CDA2EF4435B6EB70BD63BE56F4"><enum>(3)</enum><header>Relation to pediatric exclusivity for biological products</header><text display-inline="yes-display-inline">Section 351(m) of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/262">42 U.S.C. 262(m)</external-xref>) is amended by adding at the end the following:</text>
					<quoted-block display-inline="no-display-inline" id="H8E7EFF754B234D18B44D8E919E1A4FC0" style="OLC">
						<paragraph id="H59E2DA8767F34754B4CF7DDED7984255"><enum>(5)</enum><header>Relation to exclusivity for a biological product approved for a new indication for a rare disease
 or condition</header><text display-inline="yes-display-inline">Notwithstanding the references in paragraphs (2)(A), (2)(B), (3)(A), and (3)(B) to the lengths of the exclusivity periods after application of pediatric exclusivity, the 6-month extensions described in such paragraphs shall be in addition to any extensions under section 505G.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
				</paragraph></subsection></section></legis-body></bill>


